Trial reportEuropean journal of nuclear medicine and molecular imaging2024
Diagnostic efficacy of [
Trial report in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05902377 (68Ga-NY104 PET/CT Imaging in Patients With Confirmed or Suspicious Renal Cell Carcinoma), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
68Ga-NY104 PET/CT Imaging in Patients With Confirmed or Suspicious Renal Cell Carcinoma
Who cites it
14 citing papers in PubMed.
- A prospective head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Trial
- [European journal of nuclear medicine and molecular imaging · 2026Trial
- CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [European journal of nuclear medicine and molecular imaging · 2026Trial
- Rapidly progressive giant renin secreting tumor: a rare case report.Urology case reports · 2026Article
- Pancreatic Metastasis of Clear Cell Renal Cell Carcinoma: Challenges in Percutaneous Biopsy and Contrast-Enhanced Ultrasound Imaging Features.Cancer medicine · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Delayed Partial Nephrectomy After Renal Cryoablation: Whole-Lesion Histology and Clinical Course of a Single Case.Journal of clinical medicine · 2026Article
- Incidental Detection of a CAIX-avid Breast Invasive Ductal Carcinoma on 68 Ga-NY104 PET/CT During Evaluation of a Suspected Renal Mass.Clinical nuclear medicine · 2026Article
- Carbonic Anhydrase IX-Targeted Molecular Probe for Positron Emission Tomography Imaging of Clear Cell Renal Cell Carcinoma.Chemical & biomedical imaging · 2026Article
- Radiopharmaceuticals in Renal Imaging: A Comprehensive Review of Current Applications and Future Prospects.ACS omega · 2026Review
- Diagnosis and treatment of Von Hippel-Lindau syndrome: A case series.Experimental and therapeutic medicine · 2025Article
- Advances in renal cancer: diagnosis, treatment, and emerging technologies.La Radiologia medica · 2025Review
- CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma.American journal of nuclear medicine and molecular imaging · 2025Article
- Value of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeMost clear cell renal cell carcinoma (ccRCC) overexpresses carbonic anhydrase IX (CAIX). [ MATERIALS AND
methodsParticipants were prospectively recruited in the study (ClinicalTrials.gov: NCT05902377). They were further divided into two groups: group 1, patients with primary renal mass who were scheduled for surgery, group 2, patients with suspected/confirmed metastatic ccRCC. All patients underwent [
resultsA total of 47 patients (mean age, 58.8 years ± 13.5, 34 men) were recruited, including 20 patients in group 1 and 27 patients in group 2. The patient-level sensitivity, specificity, and accuracy of [
conclusions
Indexed as
Identifiers
38916753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.